The Catheter-Related Bloodstream Infection (CRBSI) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Catheter-Related Bloodstream Infection: An Overview
CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. Also known as catheter-related sepsis, it is the most common cause of nosocomial bacteremia. CRBSI occurs due to organisms like coagulase-negative staphylococcus, Staphylococcus aureus, enteric gram-negative bacilli, enterococci and streptococci, Pseudomonas, and others.
Catheter-Related Bloodstream Infection Market Key Facts
As per DelveInsight’s estimates, the incident population of CRBSI in the 7MM was found to be 674,347, in 2020.
In the US, the incidence of Gram-positive bacteria is more than Gram-negative bacteria, and very few are affected with candida species (fungi). Methicillin susceptible Staphylococcus aureus occupies the maximum patient pool among the Gram-positive bacteria, with 143,072 cases of this category, in 2020.
Among the 7MM, The estimates show a higher incidence of CRBSI in the US with 330,686 cases, in 2020.
Among EU5 countries, Germany accounted for the highest incidence of CRBSI with 62,368 cases in 2020. Whereas, the least number of cases was contributed by Spain with 16,793 cases.
France, Italy, and the UK accounted for 43,540, 32,739, and 42,570 diagnosed incident cases, respectively in 2020.
In 2020, Japan had 140,885 incidence cases and 135,454 diagnosed incidence cases.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market
Catheter-Related Bloodstream Infection Market
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted CRBSI market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.
The report gives a thorough detail of the CRBSI market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Catheter-Related Bloodstream Infection Epidemiology
The epidemiology section covers insights about the historical and current Catheter-Related Bloodstream Infection patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Catheter-Related Bloodstream Infection Epidemiology Segmentation
Total Incident Population of CRBSI
Total Diagnosed Incident Population of CRBSI
Diagnosed Incidence of CRBSI by Causative Pathogens
Catheter-Related Bloodstream Infection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CRBSI market or expected to get launched in the market during the study period. The analysis covers Catheter-Related Bloodstream Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the CRBSI Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Catheter-Related Bloodstream Infection Therapeutics Analysis
In the emerging scenario, an antibiotic lock solution therapy known as Mino-lock is being developed by Citius Pharmaceuticals to treat patients with CLABSIs/CRBSIs. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Some of the key companies in the Catheter-Related Bloodstream Infection Market include:
Citius Pharmaceuticals
Fresenius Medical Care
TauroPharm GmbH
Geistlich Pharma
CorMedix
And many others
Catheter-Related Bloodstream Infection Therapies covered in the report include:
Neutrolin
Taurosept
Taurolock
IntraLock
Mino-Lok
And many more
Get More Detailed Insights into the Emerging Therapies & Key Companies:- Catheter-Related Bloodstream Infection Therapeutics Landscape
Table of Content
1. Key Insights
2. Executive Summary
3. Catheter-Related Bloodstream Infection Competitive Intelligence Analysis
4. Catheter-Related Bloodstream Infection Market Overview at a Glance
5. Catheter-Related Bloodstream Infection Disease Background and Overview
6. Catheter-Related Bloodstream Infection Patient Journey
7. Catheter-Related Bloodstream Infection Epidemiology and Patient Population
8. Catheter-Related Bloodstream Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. Catheter-Related Bloodstream Infection Unmet Needs
10. Key Endpoints of Catheter-Related Bloodstream Infection Treatment
11. Catheter-Related Bloodstream Infection Marketed Products
12. Catheter-Related Bloodstream Infection Emerging Therapies
13. Catheter-Related Bloodstream Infection Seven Major Market Analysis
14. Attribute Analysis
15. Catheter-Related Bloodstream Infection Market Outlook (7 major markets)
16. Catheter-Related Bloodstream Infection Access and Reimbursement Overview
17. KOL Views on the Catheter-Related Bloodstream Infection Market.
18. Catheter-Related Bloodstream Infection Market Drivers
19. Catheter-Related Bloodstream Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market
Latest Healthcare Blog by DelveInsight –
Some of the technologies such as Telehealth, Mobile Apps, Robotics, At-home Diagnostics have an indispensable role in delivering quality care. Besides these, several emerging trends like Big Data, Augmented Reality/Virtual Reality, Healthcare Drones, Digital Therapeutics, and Virtual Clinical Trials, are also making rapid inroads in healthcare. The widespread adoption of these trends & technologies and their advancement is set to reshape the future of healthcare. Get key insights into leading trends that will transform the healthcare dynamics in 2022 at- 22 Healthcare Trends in 2022
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
